Kiniksa Pharmaceuticals International (MEX:KNSAN) Cyclically Adjusted PS Ratio: (As of Sep. 12, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:KNSAN Kiniksa Pharmaceuticals International PLC MEX:KNSAN
50 GF Score
Price MXN754.37
GF Value MXN549.40
! 4 Warning Signs
View Full Analysis

What is Kiniksa Pharmaceuticals International Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Kiniksa Pharmaceuticals International  (MEX:KNSAN) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Kiniksa Pharmaceuticals International Cyclically Adjusted PS Ratio Related Terms


Kiniksa Pharmaceuticals International Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Kiniksa Pharmaceuticals International's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kiniksa Pharmaceuticals International Cyclically Adjusted PS Ratio Chart

Kiniksa Pharmaceuticals International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 9.00

Kiniksa Pharmaceuticals International Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 9.00 0.00 0.00

MEX:KNSAN vs AMRX, LQDA, LNTH: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Kiniksa Pharmaceuticals International's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kiniksa Pharmaceuticals International Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kiniksa Pharmaceuticals International's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Kiniksa Pharmaceuticals International's Cyclically Adjusted PS Ratio falls into.


MEX:KNSAN
50GF Score
Kiniksa Pharmaceuticals International PLC MEX:KNSAN
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kiniksa Pharmaceuticals International Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Kiniksa Pharmaceuticals International's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec25 is calculated as:

For example, Kiniksa Pharmaceuticals International's adjusted Revenue per Share data for the fiscal year that ended in Dec25 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec25 (Change)*Current CPI (Dec25)
=154.472/139.9000*139.9000
=154.472

Current CPI (Dec25) = 139.9000.

Kiniksa Pharmaceuticals International Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201612 0.000 102.200 0.000
201712 0.000 105.000 0.000
201812 0.000 107.100 0.000
201912 0.000 108.500 0.000
202012 0.000 109.400 0.000
202112 11.530 114.700 14.063
202212 60.957 125.300 68.060
202312 63.783 130.500 68.377
202412 123.585 135.100 127.976
202512 154.472 139.900 154.472

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Kiniksa Pharmaceuticals International (MEX:KNSAN) Overvalued in 2026?

Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International stock appears to be overvalued. The current stock price of MXN754.37 is trading 37.3% above its estimated GF Value™ of MXN549.40.

Key valuation signals for MEX:KNSAN:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: MXN549.40 vs. price of MXN754.37 (37.3% above fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the MEX:KNSAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kiniksa Pharmaceuticals International Business Description

Other Exchanges KNSA:USA
Address 105 Piccadilly, Second Floor, London, GBR, W1J 7NJ
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
50GF Score

Get the complete analysis for MEX:KNSAN

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN754.37
Price
MXN549.40
GF Value